For research use only. Not for human consumption. Not medical advice — consult a licensed clinician.

GLP-1 / Metabolic

SS-31 + MOTS-c

Also known as: Elamipretide + MOTS-c blend, Mitochondrial peptide stack

Gray market

Pre-mixed blend of two mitochondria-targeted peptides marketed for cellular energy and metabolic support. SS-31 (elamipretide) is a tetrapeptide that concentrates in the inner mitochondrial membrane and binds cardiolipin, stabilizing cristae structure, reducing oxidative stress, and supporting ATP production. MOTS-c is a mitochondrial-derived peptide that activates AMPK metabolic signaling and influences glucose and lipid handling. SS-31 itself gained a narrow FDA approval (Forzinity, 2025) for Barth syndrome, but MOTS-c remains a research compound, and there is no controlled human efficacy or safety data for this specific combination — the blend is sold grey-market, not as the approved indication.

Where to buy · live market data

Who's worth your money for SS-31 + MOTS-c

Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.

No sellers for SS-31 + MOTS-c are indexed yet — we add vendors and their prices as we find them.

Watch SS-31 + MOTS-c

Get one email when the market actually moves — no newsletter, no noise.

Compound reference

About SS-31 + MOTS-c

CAS

Molecular formula

Typical dose range

Vendor-dependent; component norms: SS-31 commonly 5-25 mg/day subcutaneous in research/clinical use; MOTS-c 5-10 mg 1-3x/week subcutaneous. No validated combination dosing exists.

Half-life

SS-31: terminal half-life roughly 3-6 hours (subcutaneous, human clinical data); MOTS-c: short, not well characterized in humans

Common research uses

mitochondrial function and cellular energy support (research only)metabolic, exercise-capacity, and anti-aging interest (research only)recovery from oxidative or metabolic stress (research only)

Safety notes

This blend is not FDA-approved; it is sold as a research-only / grey-market product. SS-31 is FDA-approved only as Forzinity for Barth syndrome, not as a general metabolic or anti-aging agent and not in combination with MOTS-c. No combination-specific human safety data. Not evaluated by WADA as a blend.

Reconstitution

Reconstitute lyophilized powder with bacteriostatic water; refrigerate after reconstitution.